220px-Carbinoxamine.svg  

The US Food and Drug Administration (FDA) has approved carbinoxamine maleate extended-release (Karbinal ER, Tris Pharma), the first liquid, sustained-release histamine-H1 receptor blocker indicated for the treatment of seasonal and perennial allergic rhinitis in children aged 2 years and older, the company said.
The drug will be available in a 4 mg/5 mL oral suspension.

文章標籤

快樂小藥師 發表在 痞客邦 留言(0) 人氣()